Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K.N. Chi(BC Cancer Agency), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Karen Urtishak(Janssen (Switzerland)), Eric J. Small(CancerCare Manitoba), Gary Mason, Shiva Dibaj(Janssen (Switzerland)), A. del Corral(Janssen (United States)), Andrea Juliana Gomes, Peter Francis(Janssen (United States)), Daphne Wu(Janssen (United States)), Howard Gurney(Radboud University Nijmegen), Gerhardt Attard(London Cancer), Guilhem Roubaud(Institut Bergonié), David Olmos(Spanish National Cancer Research Centre), B. Diorio(Janssen (United States)), Elena Castro(Research Institute Hospital 12 de Octubre), Wonho Jung(Keimyung University), W. Kim(Janssen (Belgium)), Matthew R. Smith(Harvard University), Marniza Saad(University of Malaya), Shahneen Sandhu(The University of Melbourne), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center)
Cited by 195
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k